• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Sr. V.P. of Operations Citronowicz Moshe

    5/19/25 4:31:11 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care
    Get the next $APYX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    CITRONOWICZ MOSHE

    (Last) (First) (Middle)
    C/O APYX MEDICAL CORPORATION
    5115 ULMERTON ROAD

    (Street)
    CLEARWATER FL 33760

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Apyx Medical Corp [ APYX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Sr. V.P. of Operations
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Option to Buy) $1.48 05/15/2025 A 36,000 (1) 05/15/2035 Common Stock 36,000 $0 36,000 D
    Explanation of Responses:
    1. Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant.
    /s/ Moshe Citronowicz 05/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $APYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APYX

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    7/14/2023$8.00Overweight
    Stephens
    5/20/2022$12.00Buy
    Lake Street
    8/13/2021$12.00 → $14.00Market Outperform
    JMP Securities
    More analyst ratings

    $APYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Renuvion® Brings Real Transformations to the Runway at Miami Swim Week

      Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla., May 30, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of the proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, is once again taking center stage—this time at Miami Swim Week. Following the success of its groundbreaking debut at New York Fashion Week, Renuvion will proudly feature real patients on the runway, celebrating the power of transformation and self-confidence.

      5/30/25 9:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™

      The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the "FDA") for the AYON Body Contouring System™ ("AYON"). The Company is actively pr

      5/13/25 8:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation Reports First Quarter 2025 Financial Results

      Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March

      5/8/25 7:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Apyx Medical Corporation

      PRE 14A - Apyx Medical Corp (0000719135) (Filer)

      6/13/25 4:10:59 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Apyx Medical Corporation

      SD - Apyx Medical Corp (0000719135) (Filer)

      5/30/25 4:05:40 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Apyx Medical Corp (0000719135) (Filer)

      5/13/25 7:57:46 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care